Baseline characteristics of the study population
| Non-Severe disease No mechanical ventilation | Severe disease Mechanical Ventilation necessary | p-Value | ||
| n=92 | n=51 (55.4%) | n=41 (44.6%) | ||
| Inflammation parameters | ||||
| Initial CRP (mg·dL−1) | 7.9±9.0 | 4.7±5.2 | 12.6±11.3 | <0.001 |
| Peak CRP (mg·dL−1) | 15.4±12.1 | 8.5±7.9 | 25.6±9.8 | <0.001 |
| Initial PCT (ng·mL−1) | 0.41±0.73 | 0.22±0.33 | 0.68±1.04 | <0.001 |
| Peak PCT (ng·mL−1) | 4.14±13.7 | 2.95±14.2 | 5.91±12.9 | <0.001 |
| Initial IL-6 (pg·mL−1) | 189.3±737.8 | 75.3±292.4 | 359.9±1095.5 | <0.001 |
| Peak IL-6 (pg·mL−1) | 841.8±2300.5 | 118.9±321.7 | 1916.3±3352.2 | <0.001 |
| Initial WBCs (G·L−1) | 10.8±31.6 | 6.2±3.0 | 9.5±5.0 | <0.001 |
| Peak WBCs (G·L−1) | 18.1±43.2 | 8.5±4.0 | 21.5±9.7 | <0.001 |
| Specific medication | ||||
| Use of broad spectrum antibiotics# | n=58 (63.0%) | 19 (37.3%) | 39 (95.1%) | 0.01 |
| Use of Azithromycin | n=49 (53.3%) | 20 (39.2%) | 29 (70.7%) | 0.14 |
| Use of antiviral agents¶ | n=9 (9.8%) | 4 (7.8%) | 5 (12.2%) | 0.78 |
| Use of hydroxchloroquin | n=24 (26.1%) | 8 (15.7%) | 16 (39.0%) | 0.09 |
| Use of prednisolone | n=3 (3.3%) | 3 (7.3%) | ||
| Use of tocilicumab | n=4 (4.4%) | 1 (1.1%) | 3 (3.3%) | 0.23 |
Inflammation parameters and specific medication of subgroups.
CRP: C-reactive protein; PCT: procalcitonin; IL-6: Interleukin 6; WBC: White blood cell count.
#Meropenem or piperacillin and tazobactam.
¶Lopinavir/ritonavir (n=8) or Tamiflu (n=1).